Cardiac hypertrophy is a response of the myocardium to increased workload and is characterised by an increase of myocardial mass and an accumulation of extracellular matrix (ECM). As an ECM
protein, an
integrin ligand, and an
angiogenesis inhibitor, all of which are key players in
cardiac hypertrophy,
mindin is an attractive target for therapeutic intervention to treat or prevent
cardiac hypertrophy and
heart failure. In this study, we investigated the role of
mindin in
cardiac hypertrophy using littermate
Mindin knockout (
Mindin ( -/- )) and wild-type (WT) mice.
Cardiac hypertrophy was induced by aortic banding (AB) or
angiotensin II (Ang II) infusion in
Mindin ( -/- ) and WT mice. The extent of
cardiac hypertrophy was quantitated by echocardiography and by pathological and molecular analyses of heart samples.
Mindin ( -/- ) mice were more susceptible to
cardiac hypertrophy and
fibrosis in response to AB or Ang II stimulation than wild type. Cardiac function was also markedly exacerbated during both systole and diastole in
Mindin ( -/- ) mice in response to hypertrophic stimuli. Western blot assays further showed that the activation of AKT/
glycogen synthase kinase 3β (GSK3β) signalling in response to hypertrophic stimuli was significantly increased in
Mindin ( -/- ) mice. Moreover, blocking AKT/GSK3β signalling with a pharmacological AKT inhibitor reversed cardiac abnormalities in
Mindin ( -/- ) mice. Our data show that
mindin, as an intrinsic cardioprotective factor, prevents maladaptive remodelling and the transition to
heart failure by blocking AKT/GSK3β signalling.